Adenine base editors changed targeted DNA letters in human cells
Adenine base editors converted targeted A•T DNA base pairs to G•C with approximately 50% efficiency in human cells, according to research published in Nature on 25 October 2017. The resulting DNA changes had typically at least 99.9% product purity, with unwanted additions or losses of DNA letters occurring at typically no more than 0.1%. The editors also installed disease-correcting or disease-suppressing mutations in human cells without cutting through both DNA strands.
The editors worked by changing adenine, the DNA letter A, into inosine. DNA-copying enzymes read inosine as guanine, or G, allowing an A•T pair to become a G•C pair. But making that conversion required an enzyme that could act on adenine in DNA. The authors reported that no such enzymes were known.
The team adapted an enzyme that normally acts on transfer RNA, a molecule distinct from DNA. They evolved it to work on DNA and joined it to a modified CRISPR-Cas9 protein with impaired cutting activity. Repeated rounds of directed evolution and protein engineering produced the seventh-generation adenine base editors described in the study.
The work addressed a common type of disease-causing mutation: a change to a single DNA letter. C•G-to-T•A changes account for half of known pathogenic point mutations in humans, the authors stated. An editor that makes the reverse conversion could therefore advance the study and treatment of genetic diseases. The disease-correcting or disease-suppressing changes reported in this study were made in human cells.
Compared with a then-current method that used Cas9 to cut DNA, the editors introduced single-letter mutations more efficiently and cleanly, with fewer changes elsewhere in the genome. Together with earlier base editors, they allowed researchers to introduce all four transition mutations, substitutions that exchange one DNA letter for another within the same chemical class, without cutting both DNA strands.